Mani, Inc. (7730) AI Stock Analysis

• Market Cap: ¥147.83B
• Dividend Yield: 2.6%
• Average Volume (3M): 434.33K
• Price to Earnings (P/E): 28.6
• Beta (1Y): 0.84
• Revenue Growth: 5.10%
• EPS Growth: -17.80%
• Country: JP
• Employees: 4,154
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.27
• Shares Outstanding: 107,003,280
• 10 Day Avg. Volume: 818,280
• 30 Day Avg. Volume: 434,333
• PEG Ratio: 5.53
• Price to Book (P/B): 3.70
• Price to Sales (P/S): 6.79
• P/FCF Ratio: 1.50K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,419.00
• Price Target Upside: -5.43% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: ¥1,419.00 ▼(-5.43% Downside)

Mani, Inc. has a solid financial foundation with strong revenue growth and profitability, though cash flow volatility is a concern. Technical indicators suggest neutral momentum, while valuation metrics indicate fair pricing with a decent dividend yield.

Mani, Inc. Business Overview & Revenue Model

Company Description

Mani, Inc. (7730) is a Japanese company specializing in the manufacturing and sale of precision instruments and medical devices. The company is primarily involved in the dental and surgical instrument sectors, providing high-quality products used in medical procedures globally. Mani, Inc. is recognized for its innovative and reliable solutions that cater to the needs of healthcare professionals, ensuring optimal performance and safety.

How the Company Makes Money

Mani, Inc. generates revenue through the sale of its precision instruments and medical devices to healthcare providers, dental practitioners, and hospitals. The company's revenue streams are primarily driven by its extensive product portfolio, which includes dental instruments like files and reamers, as well as surgical instruments such as needles and sutures. Mani, Inc. benefits from a strong global distribution network and partnerships with medical distributors, enabling it to reach a wide customer base. Additionally, the company invests in research and development to maintain its competitive edge and meet the evolving demands of the medical industry, thereby ensuring a steady flow of income from its innovative product offerings.

Mani, Inc. Financial Statement Overview

Summary

Mani, Inc. demonstrates strong financial performance with consistent revenue growth and robust profitability margins. The balance sheet reflects financial stability with low leverage, though cash flow shows volatility due to high capital expenditures.

Income Statement

Mani, Inc. demonstrates strong financial performance with a consistent increase in revenue from 2020 to 2024. The gross profit margin has remained robust, reflecting efficient cost management. Net profit margin has improved, indicating enhanced profitability. Notably, the EBIT and EBITDA margins have shown positive trends, underscoring operational efficiency.

Balance Sheet

The balance sheet of Mani, Inc. reflects financial stability with a low debt-to-equity ratio, indicating conservative leverage. The return on equity is strong, showcasing effective use of shareholders' equity to generate profits. A high equity ratio further illustrates the company's solid financial foundation.

Cash Flow

Mani, Inc. displays a mixed cash flow performance. While operating cash flow is healthy, free cash flow has shown volatility due to significant capital expenditures in recent years. The free cash flow to net income ratio is low, suggesting potential constraints in cash availability for strategic investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.18B	28.51B	24.49B	20.42B	17.19B	15.20B
Gross Profit	18.54B	17.90B	15.42B	12.57B	11.01B	9.88B
EBITDA	9.66B	10.70B	9.94B	9.17B	7.55B	6.26B
Net Income	5.46B	6.29B	5.95B	5.29B	4.29B	3.33B
Balance Sheet
Total Assets	57.18B	57.18B	54.98B	50.11B	42.69B	39.29B
Cash, Cash Equivalents and Short-Term Investments	17.49B	21.66B	25.43B	22.73B	18.89B	17.18B
Total Debt	76.00M	83.00M	58.00M	117.00M	128.00M	62.48M
Total Liabilities	4.52B	4.85B	5.15B	4.70B	3.49B	2.72B
Stockholders Equity	52.67B	52.33B	49.83B	45.41B	39.20B	36.57B
Cash Flow
Free Cash Flow	0.00	129.00M	4.31B	4.62B	2.52B	248.97M
Operating Cash Flow	0.00	7.81B	8.03B	6.56B	6.38B	1.94B
Investing Cash Flow	0.00	-6.64B	-4.02B	-2.17B	-3.44B	-38.33M
Financing Cash Flow	0.00	-3.70B	-3.25B	-2.44B	-2.23B	-2.13B

Mani, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1500.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7730, the sentiment is Positive. The current price of 1500.5 is above the 20-day moving average (MA) of 1360.75, above the 50-day MA of 1306.72, and above the 200-day MA of 1287.35, indicating a bullish trend. The MACD of 61.03 indicates Negative momentum. The RSI at 72.48 is Negative, neither overbought nor oversold. The STOCH value of 78.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7730.

Mani, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7817	79 Outperform	$192.21B	23.53	6.38%	3.12%	2.72%	-6.31%
7716	75 Outperform	€179.19B	34.68	4.39%	2.53%	10.98%	-76.45%
7730	73 Outperform	¥147.83B	28.60	―	2.60%	5.10%	-17.80%
7780	69 Neutral	€91.59B	18.85	6.01%	2.29%	3.13%	2.91%
7979	68 Neutral	¥69.08B	16.74	―	2.72%	6.82%	-1.08%
7747	66 Neutral	$628.13B	49.29	8.67%	1.00%	11.60%	-19.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%